Newsroom

Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
(March, 2019)
View

Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS) (August, 2018)
View

New Data from the HORIZON Trial of the Hydrus® Microstent Shows Significantly Lower IOP and Medication Use at 24 Months in a US Patient Cohort (April, 2018)
View

lvantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial (April, 2018)
View

lvantis FDA Clinical Trial of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials (November, 2017)
View

lvantis Completes Pre-Market Approval Submission for the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) (October, 2017)
View

lvantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) (January, 2017)
View